# Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy

> **NCT02129699** · PHASE3 · TERMINATED · sponsor: **ETOP IBCSG Partners Foundation** · enrollment: 595 (actual)

## Conditions studied

- Lung Cancer Non-small Cell Stage IV

## Interventions

- **DRUG:** Denosumab
- **OTHER:** None, standard chemotherapy only

## Key facts

- **NCT ID:** NCT02129699
- **Lead sponsor:** ETOP IBCSG Partners Foundation
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-01-06
- **Primary completion:** 2020-02-29
- **Final completion:** 2020-02-29
- **Target enrollment:** 595 (ACTUAL)
- **Why stopped:** Completion of recruitment was not feasible as accrual was slower than anticipated. Even if a benefit for denosumab could be shown, these results would be of very limited clinical impact by the time they would be available
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02129699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02129699, "Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02129699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*